Market Research Logo

The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives


Attention: There is an updated edition available for this report.

The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives

Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence. The market for cancer testing are comprehensively covered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 5th. Edition. This report, authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:

  • Histology/Cytology
  • Immunoassays
  • Flow Cytometry
  • Rapid Tests
  • Molecular Assays
  • Tissue Arrays
  • Circulating Tumor Cells
  • Pharmacodiagnostics, Molecular
Cancer Testing: Constant Innovation

Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up.
  • New imaging modalities and digital analysis of x-ray mammograms are looking to improve the accuracy of breast cancer screening. These same imaging techniques are being used to screen patients for the metastasis of cancer from the primary site.
  • Lab testing for new cancer biomarkers - hormone, receptor and protein assays - improve the detection of cancer in patients that present with symptoms. These are now available in multiplexed tests that make better use of tissue samples.
  • With developments in the analysis of circulating cancer cells and cell free DNA in peripheral blood they are poised to help in the screening of high risk individuals.
  • Improved immunohistochemical stains and in situ hybridization make detection of cancer cells in biopsied tissue more effective. The use next generation analysis of individual tumor cells including sequencing, mass spectrometry and PCR further enhance cancer testing in tissues.
  • Bioinformatic analysis of gene and protein patterns detected in tumor cells and peripheral blood is proving to be a big breakthrough in cancer diagnosis. The technology has pinpointed gene and protein targets that will make up the next generation of cancer tumor marker panels.
  • The next big advances are related to tests based on the detection of circulating nucleic acid molecules and RNA and DNA methylation patterns.
Complete Market and Trend Analysis

Kalorama Information reports are always based on primary research of the market with particular attention to important market trends that are more important to understand than today's numbers. Shara Rosen not only defines the marketplace and provides market numbers, but her report also examines trends that are driving cancer testing now and determining where it will go in the future. Some of the trends examined in this report include:
  • Commercializing Next Generation Cancer Tests
  • Clinical Molecular Test Reimbursement Coding In The U.S.
  • Regulatory Requirements of Cancer Tests
  • Gene Patents and Test Commercialization
  • The Physician’s Role in Test Acceptance
  • Biomarkers: Issues in Research to Clinic
  • Miniaturization and Multiplexed Assays
  • The Emergence Of Non-Invasive Tools
  • Bioinformatics – Data To Information
  • Digital PCR, Mass Spectrometry, Next-Generation Sequencing
  • Sample Preparation and System Automation
  • The Role of In Vivo Cellular and Molecular Imaging
  • and Analyst Conclusions, Strategy Implications and Unmet Market Needs
Based on an analysis of these trends, the report includes a 'Technology Forecast' to 2025 that takes each particular technology used now in solid tumor testing and predicts its future role.

Personalized Cancer Testing and Advances In Precision

The phenomenon of test personalization comes under many guises – pharmacogenomic, pharmacogenetic, companion tests, and represents one of the fastest growing segments of the market for cancer tests. It has emerged fully from research into clinical practice. Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. Some personalized cancer tests are CE Marked and FDA-cleared and many more are in development. More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and are agreeing to pay for them.

This report covers those trends and has tables describing the following:
  • Most Common Cancer Drug/Gene Mutation Combinations
  • Selected Pharmacodiagnostic Histology Tests
  • Chemotherapy Resistance Tests
  • Innovations in Personalized Molecular Tests for Cancer
  • Therapeutic Drug Monitoring Immunoassays
  • Major Protein And Molecular Markers Used In Tissue Staining
Unparalleled Review of Cancer Testing Competitors: Top Tier IVD Companies And Specialist Companies

This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood - lymphomas, myelomas and leukemias - is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis. As such this report does not discuss area of hematological cancer diagnosis in great detail.

Market analysis in this report covers world markets for in vitro cancer diagnostics, however the reader will find a bias toward the developed areas of the globe -- N. America, Japan and Western Europe. However cancer is a growing global problem and where possible the report covers cancer testing in the more industrialized developing countries of Latin America and Asia Pacific.

The emphasis is on in vitro diagnostic tests, however a discussion of the role of diagnostics in cancer management, must include in vitro and in vivo tests. The two are inextricably linked. The same cell markers used in flow cytometry and antibodies used for immunoassays to detect elements of the immunity process are used as vectors for imaging agents to detect tumors and to monitor the extent of cancer metastasis.

In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles in several sections. Companies profiled include the following:

Abbott Diagnostics
Beckman Coulter Inc./Danaher
Becton, Dickinson and Company
bioMérieux Inc.
Bio-Rad Laboratories Inc.
Danaher Corporation
AB Sciex
Leica
GE Healthcare
Gen-Probe Inc.
Hologic, Inc.
IRIS International, Inc.
Novartis Diagnostics
Ortho Clinical Diagnostics
PerkinElmer, Inc.
QIAGEN N.V.
Roche Diagnostics
Siemens Healthcare Diagnostics
Sysmex Corporation
Abnova
ApoCell, Inc.
Biocept, Inc.
Clearbridge BioMedics
Cynvenio Biosystems, Inc.
Epic Sciences Inc.
Fluxion Biosciences, Inc.
Ikonisys, Inc.
NaturalNano, Inc.
On-Q-ity
ProKyma Technologies
RareCyte, Inc.
ScreenCell
Sony DADC Biosciences
Veridex, LLC
WaveSense LLC
Advanced Cell Diagnostics
Amoy Diagnostics Co. Ltd.
Applied Spectral Imaging
Biocare Medical, LLC
Biodis Biotechnology
BioMarker Strategies
Biomoda Inc.
BioView Ltd.
Bruker Corporation
CCC Diagnostics, Inc.
Caliper Life Sciences
Celerus Diagnostics
Cernostics, Inc.
ChipDX, LLC
Circadian Technologies Limited
Cymogen Dx, LLC
Dako A/S
Diagnostic Biosystems (DBS)
DVS Sciences Inc.
DxTerity Diagnostics Inc.
Halo Healthcare Inc. (formerly NeoMatrix, LLC)
HistoRx, Inc.
Horizon Discovery Ltd
iKaryos Diagnostics
IncellDx, Inc.
Leica Biosystems
Metamark Genetics, Inc.
Nodality, Inc.
Norchip
Oxford Cancer Biomarkers
Philips Handheld Diagnostics
QuantuMDx
Theranostics Health Inc.
Ventana Medical Systems Inc.
Arbor Vita Corporation
Axela Biosensors, Inc.
Binding Site (The)
BioCurex, Inc.
Biomerica Inc.
Cellmid Ltd.
Eutropics Pharmaceuticals
Fujirebio Diagnostics, Inc.
GeneTex
Gold Standard Diagnostics:
HealthLinx Limited
Immunomedics
MabCure Inc.
Matrix-Bio
Nano Discovery Inc.
Oncimmune USA LLC
OncoCyte Corp.
OncoHealth Corp.
OPKO Health, Inc.
Polymedco Cancer Diagnostic Products, LLC
Proteomika S.L.
Radient Pharmaceuticals Corporation
Saladax Biomedical, Inc.
ScheBo-Biotech AG
Wako Diagnostics
Abcodia
Adaptive Biotechnologies Corporation
Affymetrix, Inc.
Agilent Technologies Inc.
ArcticDx Inc.
Arrayit Diagnostics Inc.
Asuragen, Inc.
Autogenomics Inc.
Biocartis
Biodesix, Inc.
Cepheid
DiagnoCure
Diagnoplex SA
Enzo Biochem Inc.
Epigenomics AG
Falcon Genomics, Inc.
GeneCentric Diagnostics, Inc.
GeneNews Limited
Genetic Technologies Limited
Genomica S.A.U.
Illumina Inc.
Inform Genomics, Inc.
Ipsogen SA
Life Technologies
TrovaGene, Inc.
VolitionRx Limited

And Many More Companies..


  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
      • Table Exchange Rate Fluctuations, 2009-2012
    • SIZE AND GROWTH OF THE MARKET
      • Table Worldwide Market for Cancer In Vitro Diagnostics 2012-2017, sales $ million
      • Test Segments
        • Table Worldwide Market for Histology/Cytology Cancer IVD 2012-2017, sales $ million
        • Table Worldwide Market for Immunoassays Cancer IVD 2012-2017, sales $ million
        • Table Worldwide Market for Flow Cytometry Cancer IVD 2012-2017, sales $ million
        • Table Worldwide Market for Rapid Tests Cancer IVD 2012-2017, sales $ million
        • Table Worldwide Market for Molecular Assays Cancer IVD 2012-2017, sales $ million
        • Table Worldwide Market for Tissue Arrays Cancer IVD 2012-2017, sales $ million
        • Table Worldwide Market for Circulating Tumor Cells Cancer IVD 2012-2017, sales $ million
        • Table Worldwide Market for Molecular Pharmacodiagnostics Cancer IVD 2012-2017, sales $ million
      • Geographic Distribution
      • Market Trends
  • Introduction
    • BACKGROUND
      • Table Selected Test Gene Panel Targets (ALK, BRAF, C-Kit, EFGR, KRAS, P53, PIK3CA)
    • CANCER - DIAGNOSIS AND THERAPY MANAGEMENT
    • POINT OF VIEW
  • Market Issues In The Commercialization Of Cancer Diagnostics
    • BACKGROUND
    • DEMOGRAPHICS OF CANCER, A GLOBAL PHENOMENON
      • Table Cancer Incidence, Worldwide, By Cancer Type In 2008
    • CANCER WORLD MARKET ESTIMATE
      • Table World Cancer Test Market by Region (N. America, EU, Japan, ROW), 2007-2012
    • CANCER IN THE WORLD - SCREENING AND GOVERNMENT SUPPORTED PROGRAMS
      • Table Cancer Death Rates, by Region (Africa, Americas, Europe, Southeast Asia, Western Pacific, China, East Mediterranean, India), 2008
      • United States
      • Canada
      • Europe
      • China
      • India
      • Africa
    • COMMERCIALIZING NEXT GENERATION CANCER TESTS
    • CLINICAL MOLECULAR TEST REIMBURSEMENT CODING IN THE U.S.
      • Test Services - Route For Cancer Innovation
        • Table Selected Cancer Company Lab Service Expansions
        • Table Revenues For A Selection Of Molecular Test Service Labs, Worldwide, 2012, $ Million (Estimated)
        • Table Selected Hospital Cancer Test Services
    • REGULATORY REQUIREMENTS OF CANCER TESTS
    • GENE PATENTS AND TEST COMMERCIALIZATION
    • IMPACT OF COMPANION TEST DEVELOPMENT
      • Table Selected IVD and Pharmaceutical Company Collaborations
    • THE PHYSICIAN'S ROLE IN TEST ACCEPTANCE
  • Technological Trends That Enable The Future Of Cancer Diagnostics
    • BACKGROUND
    • BIOMARKERS: ISSUES IN RESEARCH TO CLINIC
    • MINIATURIZATION AND MULTIPLEXED ASSAYS
      • Table Selected Multiplexed Cancer Test And Service Innovations
    • THE EMERGENCE OFNON-INVASIVE TOOLS
      • Table Selected Non-Invasive Cancer Test Innovations
    • BIOINFORMATICS -DATA TO INFORMATION
      • Table Selected Information Technology Innovations In Molecular Testing
      • Table Selected App Products
    • NEW TECHNOLOGIES APPLIED TO CANCER DIAGNOSTICS
      • Overview
      • Digital PCR
      • Mass Spectrometry
        • Table Selected Cancer Tests using Mass Spectrometry
      • Chromosome Analysis
        • Table Selected Companies Involved In Chromosomal Analysis Of Cancer Cells
        • Table Selected Chromosome-Based Cancer Tests And Services
      • Next-Generation Sequencing
        • Table Sequencing Platforms Available
        • Table Selected Sequencing-Based Tests And Test Services
        • Table Selected Sample Preparation Systems for Sequencing Tests
      • Sample Preparation and System Automation
        • Table Selected Nucleic Acid Sample Preparation Products
    • THE ROLE OF IN VIVO CELLULAR AND MOLECULAR IMAGING
  • Market Analysis - Cancer Testing
    • THEMARKET FOR CANCER DIAGNOSTICS
      • Table Worldwide Market for Selected Cancer In Vitro Diagnostics (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, CTCs, Pharmacodiagnostics, Circulating Plasma DNA) 2012-2017
    • MAJOR VENDORS AND COMPANIES TO WATCH
      • Table Revenues of Selected Cancer Testing Companies $ million, estimated
      • Table Cancer Diagnostics and the Top Tier of IVD Companies
    • ACQUISITIONS,ALLIANCES AND COLLABORATIONS
      • Table Selected Acquisitions, Mergers And New Cancer Test Investments
      • Table Selected Cancer Test Collaborations
      • Table Selected Cancer Test Distribution Agreements
      • Table Selected Cancer Test Licensing Agreements
    • SCREENING -THE DEBATE CONTINUES
    • PROSPECTS FOR DECENTRALIZED CANCER TESTING
      • Table Selected POL-appropriate Cancer Test Systems
    • CANCER SPECIFIC TESTS
      • Breast Cancer
      • Colon Cancer
      • Lung Cancer
      • Ovarian Cancer
      • Pancreatic Cancer
  • Market Analysis - Cancer Tests In Clinical Chemistry
    • Selected Tissue Function Clinical Chemistry Tests
      • Table Selected Tissue Function Clinical Chemistry Tests
    • Major Players In Chemistry Analyzers and Reagents
      • Table Major Players For Clinical Chemistry Analyzers And Reagents
  • Market Analysis - Immunoassay Cancer Tests
    • ROLE OF IMMUNOASSAYS IN CANCER MANAGEMENT
      • Selected Widely Used Tumor Markers
        • Table Selected Widely Used Tumor Markers
        • Table Selected Cancer Immunoassay Technology Innovations
    • LAB-BASED ASSAYS
      • Table Selected Cancer Immunoassay Innovations
      • Table Cancer Immunoassay Sales, Lab-based (PSA, CEA, CA 125, AFP, Others), 2012-2017 (sales $ million)
    • POC - RAPID TESTS
      • Table Rapid Cancer Test Sales by Test Category (FOB, PSA, NMP22, Other) worldwide 2012-2017 (Sales $ million)
      • Colon Cancer
      • Prostate Cancer
      • Bladder Cancer
  • Market Analysis - Tissue- and Cell-based Cancer Tests
    • BACKGROUND
      • Table Selected Histology Test Services
    • MARKET OVERVIEW
      • Table Selected Innovations In Tissue-Based Cancer Tests
      • Table Worldwide Histology/Cytology Sales (Pap, in situ hybridization, immunohistochemistry, HPV, Tissue Microarrays), 2012-2017
      • Table Revenues of the Major Histology Companies, 2009-2012 $ million (estimated)
      • Table Selected Major Protein And Molecular Markers
      • Table Selected Technology Innovations In Cancer Testing
      • Pap Smear & HPV Testing
        • Table Selected HPV Test Innovations
      • Tissue Microarrays
        • Table Selected Tissue Microarray Products
      • Cell Signaling Pathway Testing
        • Table Selected Live Cell Cancer Tests
        • Table Selected New Cancer Tests And Technologies
  • Market Analysis - Cancer Tests in Flow Cytometry
    • Market Size
      • Table Selected Flow Cytometry Innovations For Cancer Testing
  • Market Analysis - Circulating Tumor Cells in Cancer Diagnostics
    • Market Size
      • Table Selected CTC Capture And Analysis Systems
  • Market Analysis - Cancer Molecular Assays
    • BACKGROUND
      • Table Selected Commercial Molecular Cancer Tests
      • Table Selected Molecular Instrumentation Innovations
      • RNA - Ribonucleic Acid
        • Table Selected RNA-Based Cancer Tests
      • Methylated Gene (meDNA) Patterns
        • Table Selected Methylated DNA tests
      • Circulating Plasma DNA
      • Minimal Residual Disease
  • Market Analysis - Personalized Cancer Testing Advances in Precision
    • BACKGROUND
      • Pharmacodiagnostic Histology
        • Table Most Common Cancer Drug/Gene Mutation Combinations
        • Table Major Protein And Molecular Markers Used In Tissue Staining
        • Table Selected Pharmacodiagnostic Histology Tests
        • Table Selected Chemotherapy Resistance Tests
        • Table Selected Innovations in Personalized Molecular Tests for Cancer
      • Therapeutic Drug Monitoring Immunoassays
  • Conclusions and Strategic Implications
    • UNMET MARKET NEEDS
  • Company Profiles: Major IVD Company Cancer Testing
    • ABBOTT DIAGNOSTICS
      • Molecular Histology
      • Companion Tests
      • Molecular Diagnostics
      • Core Lab
      • Hematology
    • ALERE
      • NMP22
    • BECKMAN COULTER INC./DANAHER
      • Core Lab
      • Immunoassays
      • Histology
      • Flow Cytometry
    • BECTON, DICKINSON AND COMPANY (BD)
      • Histology
      • Molecular
      • Flow Cytometry
    • BIOMÉRIEUX INC.
    • BIO-RAD LABORATORIES INC.
    • DANAHER CORPORATION
      • AB Sciex
      • Leica
    • GE HEALTHCARE
      • Cell Imaging
      • Sequencing
    • GEN-PROBE INC.
      • HPV
    • HOLOGIC, INC.
    • IRIS INTERNATIONAL, INC.
    • NOVARTIS DIAGNOSTICS
    • ORTHO CLINICAL DIAGNOSTICS
    • PERKINELMER, INC.
      • CLIA Lab
    • QIAGEN N.V.
      • Histology
    • ROCHE DIAGNOSTICS
      • PCR
      • Companion Tests
      • Hematological Cancers
      • Core Lab
    • SIEMENS HEALTHCARE DIAGNOSTICS
      • Histology
    • SYSMEX CORPORATION
  • Company Profiles: Circulating Tumor Cells Specialists
    • Abnova
    • ApoCell, Inc.
    • Biocept, Inc.
    • Clearbridge BioMedics
    • Cynvenio Biosystems, Inc.
    • Epic Sciences Inc.
    • Fluxion Biosciences, Inc.
    • Ikonisys, Inc.
    • NaturalNano, Inc.
    • On-Q-ity
    • ProKyma Technologies
    • RareCyte, Inc.
    • ScreenCell
    • Sony DADC Biosciences
    • Veridex, LLC
    • WaveSense LLC
  • Company Profiles: Tissue and Cell Test Specialists
    • Advanced Cell Diagnostics
    • Amoy Diagnostics Co. Ltd.
    • Applied Spectral Imaging
    • Biocare Medical, LLC
    • Biodis Biotechnology
    • BioMarker Strategies
    • Biomoda Inc.
    • BioView Ltd.
    • Bruker Corporation
    • CCC Diagnostics, Inc.
    • Caliper Life Sciences
    • Celerus Diagnostics
    • Cernostics, Inc.
    • ChipDX, LLC
    • Circadian Technologies Limited
    • Cymogen Dx, LLC
    • Dako A/S
    • Immunohistochemistry
    • Companion Diagnostics
    • Diagnostic Biosystems (DBS)
    • DVS Sciences Inc.
    • DxTerity Diagnostics Inc.
    • Halo Healthcare Inc. (formerly NeoMatrix, LLC)
    • HistoRx, Inc.
    • Horizon Discovery Ltd
    • iKaryos Diagnostics
    • IncellDx, Inc.
    • Leica Biosystems
    • Metamark Genetics, Inc.
    • Nodality, Inc.
    • Norchip
    • Oxford Cancer Biomarkers
    • Philips Handheld Diagnostics
    • QuantuMDx
    • Theranostics Health Inc.
    • Ventana Medical Systems Inc.
  • Company Profiles: Cancer Protein Marker Specialists
    • Arbor Vita Corporation
    • Axela Biosensors, Inc.
    • Binding Site (The)
    • BioCurex, Inc.
    • Biomerica Inc.
    • Cellmid Ltd.
    • Eutropics Pharmaceuticals
    • Fujirebio Diagnostics, Inc.
    • GeneTex
    • Gold Standard Diagnostics:
    • HealthLinx Limited
    • Immunomedics
    • MabCure Inc.
    • Matrix-Bio
    • Nano Discovery Inc.
    • Oncimmune USA LLC
    • OncoCyte Corp.
    • OncoHealth Corp.
    • OPKO Health, Inc.
    • Polymedco Cancer Diagnostic Products, LLC
    • Proteomika S.L.
    • Radient Pharmaceuticals Corporation
    • Saladax Biomedical, Inc.
    • ScheBo-Biotech AG
    • Wako Diagnostics
  • Company Profiles: Molecular Test Specialists
    • Abcodia
    • Adaptive Biotechnologies Corporation
    • Affymetrix, Inc.
    • Agilent Technologies Inc.
    • ArcticDx Inc.
    • Arrayit Diagnostics Inc.
    • Asuragen, Inc.
    • Autogenomics Inc.
    • Biocartis
    • Biodesix, Inc.
    • Cepheid
    • DiagnoCure
    • Diagnoplex SA
    • Enzo Biochem Inc.
    • Epigenomics AG
    • Falcon Genomics, Inc.
    • GeneCentric Diagnostics, Inc.
    • GeneNews Limited
    • Genetic Technologies Limited
    • Genomica S.A.U.
    • Illumina Inc.
    • Inform Genomics, Inc.
    • Ipsogen SA
    • Life Technologies
    • Med BioGene, Inc. (MBI)
    • MicroActive Project
    • MolecularMD Corporation
    • NanoString Technologies Inc.
    • Onconome, Inc
    • Orion Genomics
    • Oxford Gene Technology
    • Randox Laboratories Ltd.
    • RainDance Technologies, Inc.
    • Sequenom
    • Skyline Diagnostics B.V.
    • Soricimed Biopharma Inc. (formerly BioProspecting NB Inc.)
    • Transgenomic, Inc.
    • TrimGen Genetic Technology
    • TrovaGene, Inc.
    • VolitionRx Limited
  • Company Profiles: Cancer Test Service Providers
    • 20/20 GeneSystems, Inc.
    • Acupath Laboratories, Inc.
    • Advanced Laboratory Services Inc.
    • Aetna Innovation Labs
    • Agendia BV
    • Market Expansion
    • Product News
    • AltheaDx Diagnostics, Inc.
    • ARUP Laboratories
    • Atossa Genetics, Inc.
    • BC Cancer Agency
    • Beijing Genome Institute (BGI)
    • Bio-Reference Laboratories, Inc. (BRLI)
    • bioTheranostics
    • Bostwick Laboratories
    • Cancer Genetics, Inc.
    • Caris Life Sciences
    • Castle Biosciences Inc.
    • CBLPath
    • Chronix Biomedical
    • Clarient Inc.
    • CombiMatrix Molecular Diagnostics, Inc.
    • Complete Genomics
    • deCode genetics ehf
    • DiaTech Oncology
    • Everist Genomics Inc. (EGI)
    • Exact Sciences Corp.
    • Exosome Diagnostics
    • Foundation Medicine Inc.
    • GenoID Ltd.
    • Genomic Health, Inc.
    • Genoptix Medical Laboratory
    • Inostics GmbH
    • Insight Genetics
    • InterGenetics Inc.
    • Lab21 Limited
    • Laboratory Corporation of America Holdings (LabCorp)
    • Mayo Medical Laboratories
    • MDxHealth SA (formerly Oncomethylome Sciences)
    • Metabolistics Inc.
    • Mira Dx
    • MolecularMD Corp.
    • Myriad Genetics, Inc.
    • NeoGenomics, Inc.
    • Nuvera Biosciences, Inc.
    • NewGene
    • OncoPlex Diagnostics (formerly Expression Pathology Inc.)
    • OvaGene Oncology Inc.
    • Pacific Edge Diagnostics
    • Pathwork Diagnostics
    • Phenomenome Discoveries Inc.
    • Precision Therapeutics
    • Predictive Biosciences
    • Quest Diagnostics
    • Response Genetics, Inc.
    • RiboMed Biotechnologies, Inc.
    • Rosetta Genomics Ltd.
    • Sequenta, Inc. (formerly MLC Dx, Inc.)
    • Signal Genetics
    • Signature Diagnostics AG
    • Veracyte, Inc.
    • Vermillion Inc.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report